产品说明书
Vecuronium bromide
 |
同义名 : | ORG NC 45;Vecuronium (bromide);Vecuronium bromide. Brand name Norcuron.;NC 45 |
| CAS号 : | 50700-72-6 | |
| 货号 : | A233421 | |
| 分子式 : | C34H57BrN2O4 | |
| 纯度 : | 98% | |
| 分子量 : | 637.731 | |
| MDL号 : | MFCD00867762 | |
| 存储条件： |
粉末 Inert atmosphere,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 45 mg/mL(70.56 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 100 mg/mL(156.81 mM) |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Vecuronium Bromide is an aminosteriodal competitive neuromuscular blocking agent. It is used in general anesthesia as it causes muscle relaxation facilitating endotracheal intubation and to aid controlled ventilation. The pH 6 was found to be suitable for determination of VEC (Vecuronium Bromide) (pka = 8.97)[3]. Vecuronium (Bromide) produced a potent inhibition on the adult muscle-type acetylcholine receptor (IC50=8.7 nM) by competitive antagonism. Furthermore, at increasing acetylcholine concentrations, there was a significant decrease in the inhibition of the acetylcholine currents produced by 10 nM vecuronium[4]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02727712 | Coronary Heart Disease | Phase 4 | Unknown | December 2016 | China, Hunan ... 展开 >> Xiangya Hospital of Central South University Changsha, Hunan, China, 410078 收起 << |
| NCT02479581 | Valvular Heart Disease | Phase 2 | Completed | - | China, Hunan ... 展开 >> Xiangya Hospital of Central South University Changsha, Hunan, China, 410078 收起 << |
| NCT01642147 | Brain Neoplasms ... 展开 >> Surgery Hyperemia 收起 << | Not Applicable | Completed | - | China, Shanghai ... 展开 >> Huashan Hospital Shanghai, Shanghai, China, 200040 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.57mL 0.31mL 0.16mL |
7.84mL 1.57mL 0.78mL |
15.68mL 3.14mL 1.57mL |
| 参考文献 |
|---|